Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study

What Was Tested

The paper reports a study of Teduglutide (GLP-2 analog), published as a randomized controlled trial.

The researchers sought to determine correlative relationships between plasma citrulline levels, small bowel length, and PS volume.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

A post hoc analysis of plasma citrulline levels from patients in the STEPS 24-week study of teduglutide in patients with SBS-IF.

Plasma citrulline was assessed in all patients; patients were stratified 3 times into subgroups based on bowel anatomy, cause of SBS-IF, and baseline PS volumes.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Teduglutide (GLP-2 analog) and who got the comparison, which limits bias.

Correlation analyses used simple linear regression models.

Statistical comparisons between study groups were conducted using 2-sided t tests for 2 independent mean differences.

What Was Measured

Topics PubMed links to this paper include Citrulline, Colectomy, Colon, Drug Monitoring, Gastrointestinal Agents, Intestine, Small and Linear Models.

The authors tagged it with the keywords Intestinal failure, Parenteral support, Short bowel syndrome and Teduglutide.

What This Means in Plain Language

The paper is a randomized study of Teduglutide (GLP-2 analog).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Teduglutide (GLP-2 analog) compound page, all human trials.